Clinical Trial Search

Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 96.88 percentage of participants

Primary: Change in Chronic Heart Failure Health Status Between Baseline and 12 Months. — 13.5; 13.5 units on a scale

Primary: Clinician Administered PTSD Scale (CAPS) — -21.72 Change in units on a scale

Primary: Overall Survival (OS) Time — 16.3; 14.5; 13.4 Months — p=0.0328

Primary: Change From Baseline in Motion Sickness to Post Vestibular Stimulus — 5.1; 9 units on a scale — p=0.007

Primary: 6-week Change in Diameter and Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy — 4.6; 4.7; 0.1; 0.2 mm — p=<0.05

Primary: Post-op CK-MB Levels — 71.70; 92.66 IU/L — p=<0.05

Primary: Maximum Symptom Days/14 Days — 2.7 days

Primary: The Primary Endpoint of This Trial is the Proportion of Patients Alive at 1 Year. Phase II Patients Only. — 0.73 proportion of Participants

Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Sorafenib Administered With Cetuximab (400 mg/m2 Loading Dose Followed by 250 mg/m2 Weekly) — 400 mg

Primary: Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 7 Days After Last Active Vaccination — 100; 100 Percentages of subjects

Primary: To Investigate the Efficacy on Rise Time of Bright Light Therapy and Melatonin Treatment Using a 4 Armed Placebo Controlled Design. Main Outcome Measures: Sleep Log…

Primary: Mean Ex-Vivo Total Lipid Uptake Per Lens — 7.198; 35.879 micrograms

Primary: Change in Baseline Mean Serum Triglyceride Level at Study End — -103.0; -23.4 mg/dl

Primary: Serum Non-HDL Cholesterol — -3.86; -6.91; -0.91 Percent change from baseline — p=<0.05